Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q2 FY23 results · Jul–Sep 2022
Torrent Pharmaceuticals reported revenue from operations of ₹2,291.00 crore (up 7.2% from Q2 FY22) and net profit of ₹312.00 crore (down 1.3% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,291.00 | 2,137.00 | +7.2% | 2,347.00 | −2.4% |
| Other income | 16.00 | 51.00 | −68.6% | 30.00 | −46.7% |
| Total income | 2,307.00 | 2,188.00 | +5.4% | 2,377.00 | −2.9% |
| Profit before tax | 463.00 | 472.00 | −1.9% | 532.00 | −13.0% |
| Net profit for the period | 312.00 | 316.00 | −1.3% | 354.00 | −11.9% |
| EPS, basic (₹) | 9.22 | 18.63 | not comparable | 20.90 | not comparable |
| Net margin (%) | 13.6 | 14.8 | 15.1 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,928.00 | 1,799.00 | +7.2% | 1,933.00 | −0.3% |
| Other income | 11.00 | 54.00 | −79.6% | 29.00 | −62.1% |
| Total income | 1,939.00 | 1,853.00 | +4.6% | 1,962.00 | −1.2% |
| Profit before tax | 413.00 | 454.00 | −9.0% | 494.00 | −16.4% |
| Net profit for the period | 272.00 | 326.00 | −16.6% | 327.00 | −16.8% |
| EPS, basic (₹) | 8.02 | 19.24 | not comparable | 19.35 | not comparable |
| Net margin (%) | 14.1 | 18.1 | 16.9 |
Consolidated
- Filed with BSE
- 24 Oct 2022, 15:33 IST
- Board meeting
- 21 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 24 Oct 2022, 15:33 IST
- Board meeting
- 21 Oct 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Audited
- Source
- XBRL filing on BSE